Bioventix PLC (BVXP)
Industry Biotechnology
This stock can be held in an Investment ISA, SIPP and Investment Account
Sell
1,650.00p
Buy
1,750.00p
-25.00p (-1.45%)
Prices updated at 12 Dec 2025, 16:23 GMT
| Prices minimum 15 mins delay
Prices in GBX
Bioventix PLC is engaged in the field of biotechnology. Its business involves the development of high-affinity sheep monoclonal antibodies and clinical diagnostics and drugs of abuse testing.
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Income statement
Year | 2024 | 2025 |
|---|---|---|
| 14m | 13m | |
| 13m | 12m | |
| 11m | 10m | |
| 78.10 | 76.80 | |
| 8m | 8m | |
| 11m | 10m | |
| Sales, General and administrative | 2m | 2m |
| Interest expenses | - | - |
| Provision for income taxes | 3m | 3m |
| Operating expenses | 2m | 2m |
| Income before taxes | 11m | 10m |
| Net income available to common shareholders | 8m | 8m |
| 1.503 | 1.4527 | |
| Net interest income | 201,962 | 192,349 |
| Advertising and promotion | - | - |
| Net investment income, net | -42,180 | -170,006 |
| Realised capital gains (losses), net | - | - |
| Total benefits, claims and expenses | - | - |
| Earnings per share (diluted) | 1.4812 | 1.4329 |
| Free cash flow per share | 1.5723 | 1.3249 |
| Book value/share | 2.2995 | 2.2109 |
| Debt equity ratio | - | - |
Balance sheet
Year | 2024 | 2025 |
|---|---|---|
| Current assets | 13m | 12m |
| Current liabilities | 2m | 1m |
| Total capital | 12m | 12m |
| Total debt | - | - |
| Total equity | 12m | 12m |
| Total non current liabilities | - | - |
| Loans | - | - |
| Total assets | 14m | 13m |
| Total liabilities | - | - |
| Cash and cash equivalents | 6m | 5m |
| Common stock | 5m | 5m |
Cash flow
Year | 2024 | 2025 |
|---|---|---|
| Cash at beginning of period | 6m | 6m |
| Cash dividends paid | -8m | -8m |
| 8m | 7m | |
| Investments (gains) losses | 186,055 | 173,160 |
| 6m | 5m | |
| Net income | - | - |
| 8m | 7m | |
| -15,907 | -19,189 |
The figures shown in the tables are quoted in the currency of the stock selected.
Please note that past performance is not a reliable indicator of future returns. Please use the interactive graph for benchmark comparison.